Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558879 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRPSMB8PSMB5THRB | |
| SCHEMBL15281023 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRPSMB8PSMB5THRB | |
| SCHEMBL20305952 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRPSMB8PSMB5THRB | |
| SCHEMBL24802610 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRPSMB8PSMB5THRB | |
| SCHEMBL277616 | 0.97 | ALDH1A1 (0.33) | ALDH1A1TSHRPSMB8PSMB5THRB | |
| SCHEMBL17776275 | 0.92 | PSMB8 (0.32) | PSMB8PSMB5 | |
| SCHEMBL17776321 | 0.92 | PSMB8 (0.32) | PSMB8PSMB5 | |
| SCHEMBL10086616 | 0.92 | PSMB8 (0.32) | PSMB8PSMB5 | |
| SCHEMBL18751700 | 0.92 | PSMB8 (0.32) | PSMB8PSMB5 | |
| SCHEMBL17776273 | 0.92 | PSMB8 (0.32) | PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | ALDH1A1 4499/4885TSHR 40/4885PSMB8 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.